the clinical benefits as well as the cost benefits of use of recombinant interferon ( ifn ) alfa-2b instead of conventional chemotherapy ( primarily chlorambucil ) for progressive hairy cell leukemia were assessed retrospectively on the basis of 12 months of clinical data from 128 patients treated with ifn alfa-2b .
C0023443
hairy cell leukemia
C0021735
ifn